Prospective, Open-Label, Multicenter, Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and GDC-0199 (ABT-199) Vs. Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL...